With regards to their cash position, they have funding until Q3 FY2015. As they disclosed in their half year results and their quarterly Appendix 4C, they also expect to receive their R&D tax rebate of $3,3m in September/October 2014 (which was $2.3m in FY13). Plus their emerging product revenues from HiQCell and CryoShot will also help offset their cash burn.
What's happening, page-14
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
